Dr. Miller is a medical oncologist, who has dedicated his career to improving outcomes for patients with cancer, in particular, those with lung cancer. He spent 20+ years at Memorial Sloan Kettering Cancer Center where he served as an Attending Physician. His work in clinical and translational research in lung cancer culminated in observations and collaborative efforts critical to the identification of EGFR sensitizing and resistance mutations. In 2011, energized by seeing firsthand the impact of precision medicine in non-small cell lung cancer, he joined Foundation Medicine as Chief Medical Officer, and helped lead the organization through the parallel review process, and subsequent regulatory approval of its flagship assay, FoundationOneCDx. Following the acquisition of FMI by Roche, Dr. Miller joined EQRx as Physician-in-Chief and remained with EQRx through its acquisition by Revolution Medicines in 2023.

Dr. Miller has authored more than 300 peer-reviewed articles, which have appeared in such journals as Cancer Research, Clinical Cancer Research, JAMA, the Journal of Clinical Oncology and PNAS.

Dr. Miller has received the American Cancer Society Clinical Oncology Career Development Award and the Louise and Allston Boyer Award, and was recognized by the Bonnie J. Addario Lung Cancer Foundation with the Thierry Jahan “A Breath Away from the Cure” award for his efforts and contributions to lung cancer research.

More recently, Dr. Miller has served on the Board of Revolution Medicines and OneBiosciences while working as a strategic advisor/consultant to several companies which offer promising approaches for developing better predictive biomarkers or therapeutics for patients with cancer.